Day Zero Diagnostics has raised $8.6 million to further develop a sequencing-based rapid diagnostic that identifies, within hours, both the species and the antibiotic resistance profile of a bacterial pathogen.
The Mountain View, CA-based company received a nod from FDA for the MUTYH-Associated Polyposis Genetic Health Risk report.
The donor-derived cell-free DNA test was developed by the National Institutes of Health/National Heart Blood and Lung Institute.
The test, developed by Researchers at the Institute for Global Food Security at Queen’s University Belfast, can detect proteases, enzyme markers that are responsible for the progression of many diseases.
The first donor-derived cell-free DNA test to assess allograft health in kidney transplant patients is also beneficial for repeat transplant recipients, a new study finds.
The Boulder, CO-based company has been granted a Breakthrough Device Designation for its liquid biopsy and tissue specimen assay.
CellMax Life has developed a blood test that it says can identify precancerous adenomas with similar accuracy as colonoscopy, which may facilitate better compliance with screenings and increase detection rates.
A study from Mayo Clinic researchers shows less than two thirds of women ages 30 to 65 were up-to-date with cervical cancer screenings in 2016, which is below the 81% screening compliance rate self-reported in the 2015 National Health Interview Survey.
The two companies will look at advancing the development and commercialization of diagnostic tests for early detection of the disease.
An initiative at Nottingham University Hospital in Nottingham, England is making it easier for pediatric transplant patients and their caregivers to collect blood samples at home for therapeutic drug monitoring.
A team from Brigham and Women’s Hospital are developing a test that can detect tau protein, a calling card for Alzheimer’s disease.
The Menlo Park, CA-based company’s 50,000-patient trial will launch in 2019 and could be one of the most significant events of the year for the liquid biopsy market.